logo
ScreenersREIT EarningsREIT SectorsIndustries
Logo

Phio Pharmaceuticals Corp.

PHIO

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell tranā€¦ read more

Healthcare

Biotechnology

14 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$1.03

Price

+0.49%

$0.00

$1.03

Previous Close

$1.03

Open

Premium

52w Discount
Market Cap

$11.966m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financial Reports

Key metrics over the past few years and other important metrics. Amounts in USD.

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$0.00

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

-$10.932m

-25.7%

1y CAGR

-4.5%

3y CAGR

-1.9%

5y CAGR
EPS

-$1.43

+1.4%

1y CAGR

+13.4%

3y CAGR

+22.0%

5y CAGR
Book Value

$16.462m

$17.412m

Assets

$950k

Liabilities

-

Debt
Debt to Assets

0.0%

-

Debt to EBITDA
Free Cash Flow

-$10.717m

-34.1%

1y CAGR

-4.2%

3y CAGR

-0.1%

5y CAGR
No items found.
Press Releases
Statements and updates from the company
ā†‘ TopSummaryPriceFinancialsPress Releases
logo
About usFAQ
All the information presented is collected from official and public documents such as: Quarterly and Annual Reports, 10-K (US), Information Form (Canada), Presentations and the Investor Relations (IR) section of the company's website.
The data displayed by alreits.com is solely for informational purposes, we do not recommend the buying, holding or selling of any of the stocks on the website. If you have no experience in the stock market, please talk to your personal licensed investment advisor before making any decisions.